Company: RENEF
Filing Date: 2025-10-08
Form Type: PRE 14A
Source: 0001104659-25-097940
Chunk: 29

Company: Cartesian Growth Corp II
Filing Date: 2025-10-08
Form: PRE 14A
Chunk 29
---
 or electronically)
to the transfer agent at the address below prior to 5:00 p.m., Eastern Time, on October [ ], 2025 (two
business days prior to the vote at the Extraordinary General Meeting). If you have questions regarding the certification of your position
or delivery of your shares, please contact:

Continental Stock Transfer & Trust
Company

One State Street Plaza, 30th Floor

New York, NY 10004

Attn: SPAC Redemption Team

E-mail: spacredemptions@continentalstock.com

<div align='center'>11

RISK FACTORS</div>

In addition to the below
risk factors, you should consider carefully all of the risks described in our Annual Report on Form 10-K for the year ended December
31, 2024, any subsequent Quarterly Report on Form 10-Q filed with the SEC, and in the other reports we file with the SEC before making
a decision to invest in our securities. The risks and uncertainties described in the aforementioned filings and below are not the only
ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become
important factors that adversely affect our business, financial condition and operating results or result in our liquidation.

We cannot assure you that the Extension will enable us to complete a business combination.

Approving the Extension and
not redeeming your shares involves a number of risks. Even if the Extension is approved, we cannot assure you that a business combination
will be consummated prior to the Extended Date. Our ability to consummate any business combination is dependent on a variety of factors,
many of which are beyond our control. If the Extension is approved, we expect to seek shareholder approval of a business combination.
We are required to offer shareholders the opportunity to redeem shares in connection with the Extension Proposal, and we will be required
to offer shareholders redemption rights again in connection with any shareholder vote to approve a business combination. Even if the
Extension or a business combination are approved by our shareholders, it is possible that redemptions will leave us with insufficient
cash to consummate a business combination on commercially acceptable terms, or at all. The fact that we will have separate redemption
periods in connection with the Extension and a business combination vote could exacerbate these risks. Other than in connection with
a redemption offer or liquidation, our shareholders may be unable to recover their investment except through sales of Ordinary Shares
on the open market.